Caricamento...
Population pharmacokinetic–pharmacodynamic analysis for eribulin mesilate-associated neutropenia
AIMS: Eribulin mesilate is an inhibitor of microtubule dynamics that is approved for the treatment of late-stage metastatic breast cancer. Neutropenia is one of the major dose-limiting adverse effects of eribulin. The objective of this analysis was to develop a population pharmacokinetic–pharmacodyn...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Blackwell Science Inc
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3769668/ https://ncbi.nlm.nih.gov/pubmed/23601153 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12143 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|